Compound Information | SONAR Target prediction | Name: | AMANTADINE HYDROCHLORIDE | Unique Identifier: | SPE01500110 | MolClass: | Checkout models in ver1.5 and ver1.0 | Molecular Formula: | | Molecular Weight: | 169.566 g/mol | X log p: | -0.732 (online calculus) | Lipinksi Failures | 0 | TPSA | 0 | Hydrogen Bond Donor Count: | 0 | Hydrogen Bond Acceptors Count: | 1 | Rotatable Bond Count: | 0 | Canonical Smiles: | Cl.NC12CC3CC(CC(C3)C1)C2 | Source: | synthetic | Therapeutics: | antiviral, antiparkinsonian; treatment of drug-induced extrapyrimidal reactions | Generic_name: | Memantine | Chemical_iupac_name: | 3,5-dimethyladamantan-1-amine | Drug_type: | Approved Drug | Pharmgkb_id: | PA10364 | Kegg_compound_id: | C13736 | Drugbank_id: | APRD00221 | Melting_point: | 258 oC (HCl salt) | H2o_solubility: | 35 mg/mL (HCl salt), 0.9 mg/mL for free base | Logp: | 2.197 | Cas_registry_number: | 19982-08-2 | Drug_category: | Dopamine Agents; Antiparkinson Agents; Antidyskinetics; Excitatory Amino Acid Antagonists; Central Nervous System Agents; ATC:N06DX01 | Indication: | For the treatment of moderate to severe dementia of the Alzheimer-s type. | Pharmacology: | Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer-s disease. It differs from traditional agents used in Alzheimer-s disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer-s disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer-s disease. | Mechanism_of_action: | Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells and ultimately neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. | Organisms_affected: | Humans and other mammals |
Species: |
4932 |
Condition: |
ARL3 |
Replicates: |
2 |
Raw OD Value: r im |
0.6743±0.00219203 |
Normalized OD Score: sc h |
1.0194±0.00877196 |
Z-Score: |
0.9202±0.442263 |
p-Value: |
0.380548 |
Z-Factor: |
-4.59554 |
Fitness Defect: |
0.9661 |
Bioactivity Statement: |
Nonactive |
Experimental Conditions | | Library: | SPECMTS3 | Plate Number and Position: | 2|B9 | Drug Concentration: | 50.00 nM | OD Absorbance: | 600 nm | Robot Temperature: | 24.10 Celcius | Date: | 2008-06-11 YYYY-MM-DD | Plate CH Control (+): | 0.0403±0.00059 | Plate DMSO Control (-): | 0.657225±0.01365 | Plate Z-Factor: | 0.9334 |
| png ps pdf |
7170481 |
[(1S,2R,4S)-1,7,7-trimethylnorbornan-2-yl]azanium |
7170956 |
[(1S,2S,4R)-1,3,3-trimethylnorbornan-2-yl]azanium |
7170957 |
(1S,2S,4R)-1,3,3-trimethylnorbornan-2-amine |
7173891 |
[(1R,2R,4S)-1,3,3-trimethylnorbornan-2-yl]azanium |
7173892 |
(1R,2R,4S)-1,3,3-trimethylnorbornan-2-amine |
7177099 |
[(1R,2R,5R)-5-methyl-2-propan-2-yl-cyclohexyl]azanium |
internal high similarity DBLink | Rows returned: 12 | 1 2 Next >> |
active | Cluster 6660 | Additional Members: 3 | Rows returned: 0 | |
|